Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.69 |
| ▸ | PDE5A | O76074 | 3/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8357568 | 0.91 | ADORA1 (0.70) | ADORA1ADORA2APDE5AACP1ADORA3 | |
| SCHEMBL4251897 | 0.89 | ADORA1 (0.70) | ADORA1ADORA2APDE5AACP1MTNR1A | |
| SCHEMBL8357988 | 0.89 | ADORA1 (0.70) | ADORA1ADORA2APDE5AACP1ADORA3 | |
| SCHEMBL4253759 | 0.89 | ADORA1 (0.88) | ADORA1ADORA2APDE5AADORA3KDM4E | |
| SCHEMBL8358180 | 0.86 | ADORA1 (0.88) | ADORA1ADORA2APDE5AADORA3KDM4E | |
| SCHEMBL8357570 | 0.86 | ADORA1 (0.69) | ADORA1ADORA2APDE5AADORA3 | |
| SCHEMBL4259710 | 0.82 | ADORA1 (0.70) | ADORA1ADORA2APDE5AACP1MEN1 | |
| SCHEMBL4259473 | 0.82 | ADORA1 (0.80) | ADORA1ADORA2APDE5AADORA3KDM4E | |
| SCHEMBL4253074 | 0.82 | ADORA1 (1.00) | ADORA1ADORA2AADORA3KDM4EALDH1A1 | |
| SCHEMBL4253955 | 0.82 | ADORA1 (0.69) | ADORA1ADORA2APDE5AACP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2003048120-A2 | 2-ARYL PYRROLOGPYRIMIDINES FOR A1 AND A3 RECEPTORS | OSI PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | ADORA1 2/4885ADORA2A 3/4885PDE5A 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.